



---

**SUGGESTED FORMULA**

---

**Neuropathic in Liposome Pregab and Ephedrine (4/1/4/4/4/10/0.2 %**

Version number: 1.0

Volume: 30gm

---

Carbamazapine, USP (CA250)*	1.2GM
Lidocaine Hydrochloride, USP (LI103)	0.3GM
Ketamine Hydrochloride, USP (K1068)	1.2GM
Ketoprofen, USP (K1155)	1.2GM
Gabapentin, USP (G1092)	1.2 GM
Lyrica <sup>®</sup> 300mg Capsules (Commercial)	10 Capsules
Ephedrine Sulfate, USP (EP120)	0.06GM
Niosome Cream, Heavy (B4506)	30 GM Q.S.

---

**SUGGESTED COMPOUNDING PROCEDURES**

1. Triturate all powders together
2. Open Lyrica<sup>®</sup> capsules and add to Step 1
3. Q.S. with Niosome Cream and mix well
4. Mill all ingredients
5. Check for "grit" by rubbing a small amount on the back of your gloved hand, mill again if necessary

---

Suggested Quality Assurance Checklist:

% Calculation: \_\_\_\_\_

No Grit: \_\_\_\_\_

Correct Auxiliary Labels: \_\_\_\_\_

Room Temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.

It is recommended that you follow USP <795> recommendations for potency testing.

**Beyond-Use Date is estimated to be 30 days**

\*Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

05/18 JD